Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.

Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create ...

Moderna’s stock (NASDAQ: MRNA) has plummeted over 80% in the past year, largely due to challenges in its vaccine sales. Last year, the company announced lower sales projections in Europe following the ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...